Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameMega Genomics
Stock Code06667
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中國領先的基因檢測平台公司,專注於消費級基因檢測及癌症篩查服務,提供涵蓋營養與代謝、癌症風險評估、慢性疾病易感性、藥物遺傳學檢測及傳染病檢測的基因檢測服務,並提供結直腸癌及胃癌等非侵入性癌症篩查。
Listing Date2022-06-22
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京海淀區花園北路健康智谷401
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitemegagenomics.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 18.00 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 3,600
Par ValueTo be extracted
Offer Period2022-06-10 to 2022-06-15
Global Offering Shares11,961,800 shares
HK Public Offer Shares (Initial)1,196,200 shares (10.0%)
Public Offer Lots (Initial)5,981lots (Pool A2,990lots,Pool B2,991lots)
International Placing Shares (Initial)10,765,600 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO239,233,800 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share81.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 215,312,400

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 3,600
2 lots 400 HK$ 7,200
3 lots 600 HK$ 10,800
4 lots 800 HK$ 14,400
5 lots 1,000 HK$ 18,000
6 lots 1,200 HK$ 21,600
7 lots 1,400 HK$ 25,200
8 lots 1,600 HK$ 28,800
9 lots 1,800 HK$ 32,400
10 lots 2,000 HK$ 36,000
15 lots 3,000 HK$ 54,000
20 lots 4,000 HK$ 72,000
25 lots 5,000 HK$ 90,000
30 lots 6,000 HK$ 108,000
35 lots 7,000 HK$ 126,000
40 lots 8,000 HK$ 144,000
45 lots 9,000 HK$ 162,000
50 lots 10,000 HK$ 180,000
100 lots 20,000 HK$ 360,000
150 lots 30,000 HK$ 540,000
200 lots 40,000 HK$ 720,000
250 lots 50,000 HK$ 900,000
300 lots 60,000 HK$ 1,080,000
350 lots 70,000 HK$ 1,260,000
450 lots 90,000 HK$ 1,620,000
500 lots 100,000 HK$ 1,800,000
1,000 lots 200,000 HK$ 3,600,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,500 lots 300,000 HK$ 5,400,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 1.52B
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +519%

Valuation & Financials

Market Cap (at Offer Price)HK$ 4,306,208,400
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣79.0百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201920202021
Revenue 123,700203,220237,185
Cost of sales -45,224-56,979-70,509
Gross profit 78,476146,241166,676
Other income and gains, net 14,5243,68014,265
Selling and distribution expenses -4,944-19,475-22,977
Administrative expenses -15,583-18,553-22,968
Net finance costs -3,052-1,851-785
Profit before tax 38,29294,90395,882
Income tax expense -8,601-15,806-16,867
Profit for the year 29,69179,09779,015
Profit attributable to owners 29,69179,09779,015
Balance Sheet
Item 201920202021
Cash and cash equivalents 52,646208,450239,096
Trade and bills receivables 108,125130,234203,630
Inventories 2,4402,9723,284
Total current assets 184,380358,108685,362
Total assets 263,745453,573772,183
Total current liabilities 53,069262,36569,791
Total liabilities 266,447277,17877,687
Total equity -2,702176,395694,496
Equity attributable to owners -2,702176,395694,496
Interest-bearing borrowings 13,0602,6540
Cash Flow Statement
Item 201920202021
Net cash from operating activities 37,272102,83630,629
Net cash from investing activities 17,668-31,087-1,714
Net cash from financing activities -20,27984,0552,620
Net increase in cash 34,661155,80431,535
Depreciation of PP&E 8,5738,5328,355
Depreciation of right-of-use assets 5,4125,4115,412
Amortisation of intangible assets 6993106
Purchase of PP&E -581-1,045-4,159
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 18.0
First Day OpenHK$ 19.48
First Day Change-61.39%
First Day Volume3858800.0
First Day Turnover74244600.0
Use of Proceeds
1、約30%或46.0百萬港元將用于我們的消費級基因檢測及癌癥篩查服務及產品的銷售、營銷及商業化; 2、約25%或38.4百萬港元將投資于研發我們的服務及產品; 3、約20%或30.7百萬港元將用于增加或擴大我們的檢測能力及產能; 4、約15%或23.0百萬港元將用于通過投資或收購具吸引力的技術或檢測相關公司,為我們在整個行業價值鏈的擴張提供資金; 5、約10%或15.3百萬港元預期將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中信建投(国际)融资有限公司 CE BAU112
Overall Coordinators (3)
中信建投(国际)融资有限公司 CE BAU112 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855
Joint Bookrunners (7)
中信建投(国际)融资有限公司 CE BAU112 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940 Livermore Holdings Limited CE BJN764 国泰君安证券(香港)有限公司 CE ABY236
Joint Lead Managers (7)
中信建投(国际)融资有限公司 CE BAU112 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 富途证券国际(香港)有限公司 CE AZT137 老虎证券(香港)环球有限公司 CE BMU940 Livermore Holdings Limited CE BJN764 国泰君安证券(香港)有限公司 CE ABY236

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 迈克生物股份有限公司 58,158,000 HKD — 27.01% — 6 months 2022-12-22
2 南昌工控园区股权投资合伙企业(有限合伙) 81,414,000 HKD — 37.81% — 6 months 2022-12-22
3 南昌金融控股有限公司 34,898,400 HKD — 16.21% — 6 months 2022-12-22

Directors & Management

PositionChinese nameEnglish Name
Chairman林琳—
Company Secretary李艷、伍偉琴—
No director data available.

Major Shareholders

Major Shareholders & HoldingsMei Nian Investment Limited(美年大健康)15.57%;俞博士18.73%;受限制股份單位代名人(嘉士圖有限公司)11.40%;郭女士9.20%;天津世紀宇能企業管理合夥企業(有限合夥)5.06%
About this page

This page shows Mega Genomics (06667) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect